Industrial Biotechnology Congress is a remarkable event and a niche gathering of Biotechnologists, Industrialists, Scientists, Technocrats, Leading Universities and Research Institutions making the Congress a perfect platform to share experience, foster collaboration across Industry and Academia, and evaluate transpiring technologies across the globe. The theme of congress “Milestones of Innovative Scientific Research in Biotechnology & its Industrial Applications” reflects the emerging progress being made in Biotechnology Industry. Biotech investing is no longer a pie-in-the-sky game. The first century of the new Millennium will belong … also to biotechnology which will bring unprecedented advances in human and animal health, agriculture and food production, manufacturing and sustainable environmental management. This Congress proclaims the technical bottlenecks, and the scientific advances, that affect the extent and pace of biotechnological input into cleaner products and processes. Industrial Bio-2015 officially welcomes all the participants across the globe to attend the Industrial Biotechnology Congress during August 10-12, 2015 at Birmingham, United Kingdom.
Birmingham a city in the West midlands of England is the Britain's second largest metropolitan economy. The city is a major international commercial centre and an important transport, retail, events and conference hub. The national biotechnology sector in United Kingdom has continued to expand, with sector growth rates outperforming those of the previous years. The largest segment in terms of turnover is the specialist services segment with £200m of turnover based on providing services, equipment and materials into the sector in the UK and overseas. The production of industrial enzymes, a particularly strength of the European region, is another significant market with a global value of £1.9bn in 2011 for products used in the food, brewing, detergent and animal feed industries. The market in 2011 was estimated at £32bn based on the market value of products such as amino acids, glycerin, lactic acid, vitamins and alcohols and involves some 4,000 companies worldwide.Industrial biotechnology conferences birmingham is going be a great event for all the Industrial biotechnologists.
The three day industrial biotechnology events will address key issues concerning biotechnology applications in industry.organized around daily themes, the congess focuses on moving from present knowledge to future solutions.
OMICS International organizes 300+ International Conferences every year across USA, Europe & Asia with support from more than 1000 scientific societies and publishes 400+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.
For further details, kindly have a glance on : http://www.conferenceseries.com/industrial-biotechnology-nanobiotechnology--microbiology-bioprocess-fermentation-technology.php
Industrial biotechnology conferences 2015 is an excellent oppurtunity for all the delegates from universities and institutes to interact with the world class scientists.
industrial biotechnology symposiums Omics international confernce and symposiums is unlike any event
Industrial biotechnology conferences 2016 aim is to provide a platform for the exchanging of the latest achievements in industrial biotechnology, as well as to communicate industrial need and research opportunities. It is an opportunity to take part in and to influence future trends in one of the fastest growing industry sectors.
Biotechnology Industries
Biotechnology industry analysis (known mainly in Europe as white biotechnology) is the application of biotechnology for industrial purposes, including industrial fermentation. It includes the practice of using cells such as micro organisms, or components of cells like enzymes, to generate industrially useful products in sectors such as chemicals, food and feed, detergents, paper and pulp, textiles and biofuels. A series of derived terms have been coined to identify several branches of biotechnology: Blue biotechnology (aquatic applications of biotechnology), Green biotechnology ( environmentally friendly solutions to agricultural processes), Red Biotechnology (engineering of medical processes), White Biotechnology (resource-saver in industrial processes).
The investment and economic output of all of these types of applied biotechnologies is termed as "bioeconomy". Biopharma is the largest sector contributing about 62%of the total revenue followed by bioservices (18%), bioagri (15%), bioindustry (4%), and bioinformatics contributing (1%). The Indian biotechnology sector is expected to grow from the current US$ 5-7 billion to US$ 100 billion by 2025 by doubling the growth rate of this sector from 15% to 30%, according to the Association of Biotechnology Led Enterprises (ABLE).The industrial biotechnology conferences 2015 is going to be a great platform for all industries working on biotechnology.
Growth rate: biotechnology industry statisticsThe global biotechinology industry is forecast to exceed $320 billion by 2015. Market growth is fuelled by economic recovery, increased R&D funding, government initiatives and biotechnology used in agriculture and medical sciences. Developing nations particularly India and China, are becoming major markets in the field of industrial biotechnology. In the areas of genetic testing by 2010 the market was worth $1.5 billion and is expected to reach $ 4 billion by 2015. The US dominates the global biotechnology industry followed by EU nations.
Target Audience will be personnel from both industrial and academic fields which include; CEOs, COOs, Directors, Vice Presidents, Co-directors, Biotechnologists, Managing Directors, Industry Safety Officers, Environmental & Plant Scientists, Doctorates, Professors, Post Doctorate Fellows, Vendors of Consumer Products/ Managers, Pharmaceutical Scientists, Students from the related fields.
Biotech Food Industry
Biotechnology as applied to food processing in most developing countries makes use of microbial inoculants to enhance properties such as the taste, aroma, shelf-life, texture and nutritional value of foods. These high value products are increasingly produced in more technologically advanced developing countries for use in their food and non-food processing applications.
Scope and Importance: Biotech has rapidly emerged as an area of activity having marked impact on almost all domains of human welfare ranging from : Plant sciences, Food processing, protecting environment, protection, production and productivity, trade, economics and economy.
A range of technologies is applied at different levels and scales of operation in food processing across the developing world. Conventional or “low-input” food processing technologies include drying, fermentation, salting, and various forms of cooking, including roasting, frying, smoking, steaming, and oven baking. Food processing is a process by which non-palatable and easily perishable raw materials are converted to edible and potable foods and beverages, which have a longer shelf life.
Market size: Biotechnology covers a broad spectrum of useful products and technologies derived from living systems and organisms. Biotech uses biological processes such as fermentation and harnesses biocatalysts such as enzymes, yeast, and other microbes to become microscopic manufacturing plants for a new type of agriculture in food and beverage industry.
Industrial Biotechnology statistics and analysis
Biotechnology industry statistics Biotechnology uses biological systems or living organisms for the development of its products, mostly biopharmaceutical drugs. The key regions for the global biotech industry are the United States, Europe, Canada and Australia. About 600 companies and 170 thousand employees in these countries generate some 90 billion U.S. dollars of biotech revenue. Globally, around 160 billion U.S. dollars were spent on biopharmaceuticals in 2011. This figure is expected to exceed 200 billion U.S. dollars by 2016.
Industrial Biotechnology Market and Business opportunities Industry Trends: Biotechnology is becoming an increasingly important part of product development in a variety of industries. Biotechnology refers to the use of living organisms, or their products, to modify human health and the human environment. While genetically modified products remain controversial, attitudes are beginning to change, with the increasing acceptance of the process within agricultural industries and across other sectors. The Global biotechnology industry is in the growth phase of its economic life cycle. Over the five years to 2014, revenue and industry value added (IVA) growth have outpaced world GDP growth. IVA, which measures the industry's contribution to the overall global economy, is forecast to grow 10.8% per year on average during the 10 years to 2019, well in excess of annualized global GDP growth of 3.6% over the same period. The rapid increase in demand reflects the significant expansion in the products the industry supplies. Product lines increase as new technology is developed, processes are learned and products commercialized.
The global biotechnology industry had total revenues of $323.1bn in 2014, representing a compound annual growth rate (CAGR) of 7.2% between 2010 and 2014. The medical/healthcare segment was the industry's most lucrative in 2012, with total revenues of $182.5bn, equivalent to 60.0% of the industry's overall value. The performance of the industry is forecast to decelerate, with an anticipated CAGR of 5.7% for the five-year period 2014 - 2019, which is expected to drive the industry to a value of $427.3bn by the end of 2019.
There are 55 companies in the UK whose prime activity and turnover is derived directly from the application of biotechnology to make industrial products. The sector shows a turnover of £308m in 2010 and employs over 1000 people. Fine & speciality chemicals, food & drink, and biofuels make up the largest number of product and process companies, representing 48% of the sector turnover. The most frequently employed technology across the sector is fermentation followed by biomass processing.even small biotech companies are gaining profits by applying innovative thoughts of biotechnology in industry field.
Biotechnology opportunities The industrial biotechnology sector is mainly composed of SMEs with 86% of the companies being formed over four years ago. Overall between 2009 and 2010, the comparison shows a large increase in employment of 16% and a 2% decrease in turnover. These numbers mask a strong performance in the pharmaceutical intermediates segment and a 19% decrease in turnover for biofuel companies.
Biotech bussiness plan
One of the things that make the biotech industry unique is the significant amounts of money that businesses will need to develop a product. While internet or software companies can commercialize a product through bootstrapping or after just one round of seed funding, a biotech firm will typically need three, four, or even more rounds of fundraising. On average, it costs between $25 million to $100 million to develop new medical diagnostics and devices, and more than $1 billion to take new drugs from the laboratory through regulatory approval to sales.
Biotech Products and Market Research
Biotechnology covers a broad spectrum of useful products and technologies derived from living systems and organisms. Diagnostics now include DNA, RNA, RNAi, aptamers, microarrays, tissue arrays, biomarkers and companion diagnostics - all heading toward being paired up with next generation sequencing technologies such as emerging nanopore platforms. Biotech uses biological processes such as fermentation and harnesses biocatalysts such as enzymes, yeast, and other microbes to become microscopic manufacturing plants for a new type of agriculture.
Industry Trends: In the past five years, the global recession tempered demand for non-essential health products and reduced funding for biotechnology research and development from private investors. Despite these factors, industry firms thrived on the back of technological advances that facilitated new discoveries and stimulated greater demand from firms in the pharmaceutical and agricultural sectors. Industry growth is forecast to continue skyrocketing in the next five-year period as investment in biotechnology from around the world
Industrial Biotechnology Regulations and Policies
Biotechnology law is a rapidly growing, highly specialized field of law, closely associated with pharmaceutical law and stemming from the field of science and technology. Despite its specialized nature, this area of law does overlap with a few other main practice areas:intellectual property law; patent law (and specifically, patent prosecution); licensing law; litigation; business law; and venture capital la
The 2014 guidance is largely similar in layout to FDA's 1998 guidance, but instead focused on biotechnology products—gene therapies, vectored vaccines, and related recombinant viral or microbial products (GTVVs)—submitted under a Biologics License Application (BLA) instead of pharmaceuticals submitted under a New Drug Application (NDA
IB and Health Care
Healthcare biotechnology refers to a medicinal or diagnostic product or a vaccine that consists of, or has been produced in, living organisms and may be manufactured via recombinant technology. This technology has a tremendous impact on meeting the needs of patients and their families as it not only encompasses medicines and diagnostics that are manufactured using a biotechnological process, but also gene and cell therapies and tissue engineered products.
Biotechnology has been used for more than 6,000 years for lots of interesting and practical purposes: making food such as bread and cheese, preserving dairy products and fermenting beer. No other industry is better placed to enhance quality of life and respond to society’s ‘Grand Challenges’ of tackling an ageing and ever increasing population, healthcare choice and affordability, resource efficacy, food security, climate change and energy shortages.
Advances in pharmaceutical and biotechnology sciences have led to increasing numbers of novel drugs and biological products entering clinical development (drugs and biological products will be referred to collectively as drugs unless otherwise specified). One of the fastest growing areas of pharmaceutical research is the development of drugs intended for the treatment of rare diseases — also referred to as orphan diseases — which are defined as diseases or conditions that affect fewer than 200,000 persons in the United States (Braun et al., 2010; Orphan Drug Act, 1983).
Biotech Market Size
Today, 418 new biotech medicines and vaccines are being tested for more than 100 diseases, among which 210 to treat cancer, 50 to treat infectious diseases and 44 to treat autoimmune disorders. Biotech medicines are estimated to account for approximately 20% of all marketed medicines and represent 50% of all medicines in the pipeline. Biotechnology has a major impact on the provision of safe and effective vaccines against infectious diseases. Biotechnology also provides safe recombinant alternatives to proteins derived from human blood or tissue.
Industrial environmental Biotechnology
Environmental biotechnology can simply be described as "the optimal use of nature, in the form of plants, animals, bacteria, fungi and algae, to produce renewable energy, food and nutrients in a synergistic integrated cycle of profit making processes where the waste of each process becomes the feedstock for another process. The Industrial and Environmental Biotechnology group focuses on the sustainable utilization of natural resources, biological production of renewable energy carriers (hydrogen, alcohols, electricity, methane), microbial biomass-based feed-stocks for fuel, and metabolic engineering and synthetic biology. This is obtained through multidisciplinary research into microbiology/microbial ecology, molecular and systems biology and modelling of bioengineering systems.
The understanding of microbial bioprocess at molecular level helps in the development and optimization of industrial biotechnology for a variety of applications. For instance, bioprocess and metabolic engineering will aid in the development of improved bio-energy producing microorganisms. The general vision is that Europe will have made substantial progress towards a bio-based society by 2025, and in particular that the European chemical industry will regard biotechnology as an essential part of the process and product development tool kit. This means that the market for bioengineers likely will continue to grow in the future, and that industrial/environmental bioengineers will be one of the cornerstones in forming a sustainable society.
Modern industrial Biotechnology and Microbiology
Modern biotechnology can be defined as use of cellular, molecular and genetic processes in production of goods and services. Its beginnings date back to the early 1970s when recombinant DNA technology was first developed. Unlike traditional biotechnology – which includes fermentation and plant and animal hybridization – modern biotechnology involves a different set of technologies, including industrial use of recombinant DNA, cell fusion and tissue engineering amongst others. Modern biotechnology has widespread applications in human medicine and health care which make a significant contribution to any country’s economy.As microbiology is dealing with microorganisms transformation is the main topic for any gene to be introduced or to be modified to get more information microbial transformation conferences are execellent oppurtunities.
1. Benefits of Industrial Biotechnology: Modern biotechnology in industrial production, energy and the environment Industrial biotechnology (including modern biotechnology in industrial production processes, energy and the environment) in EU manufacturing industry is currently limited to specific processes and individual steps in the production process, including:
Textile finishing (e.g. enzyme-based de-sizing of cotton fabric);
Pulp and paper manufacturing (e.g. enzyme-supported pulp bleaching);
Detergents (e.g. enzymes in laundry and automatic dishwasher detergents);
Certain chemical products, e.g. enzymes, biotechnology-based polymers, antibiotics, amino acids, drug compounds (individual steps in the production process or fully biotechnological production).
Biotechnology in Pharmaceutical Industry
New biotechnology comprises genetic engineering, protoplast fusion and monoclonal antibody techniques, powerful new “tools” designed to generate efficient bioprocesses and products for the pharmaceutical industry. Biotech opportunities largely mirror those in the pharmaceutical Industry. The key difference is that biotech firms are much more focused on research because they are still developing their initial products. Biotech firms tend to expand their marketing and sales forces when-and if-a viable product nears FDA approval. Biotech and pharma have been performing exceedingly well relative to other industries in recent years. And while there are problems lurking in the shadows at some companies, overall the future looks bright for these industries. Though there is plenty of public controversy (e.g., the moral and ethical questions surrounding genomics and the pricing and patent practices of Big Pharma), demand for drugs is growing, fueled by an aging population and blossoming international markets. Regardless of whether you choose to work for Big Pharma or small biotech, don't get too attached to the status quo.
Working with plant- and chemical-based compounds, pharmaceutical companies work their mojo to make medicines that cure some diseases, manage others, and protect us from infection in the first place. Big Pharma is one of the world's most profitable industries. During the last 30 years, the industry has spent billions of dollars on research and reaped billions in return. In 2006 alone, the pharmaceutical industry introduced 31 major drugs and sold $643 billion in products worldwide-a 7% increase over 2005 sales, according to the drug market research firm IMS Health. U.S. sales beat the national average with growth of 8.3 % (up from 5.4 % growth in 2005).
Biotechnology Industry market analysis
Biotechnology covers a broad spectrum of useful products and technologies derived from living systems and organisms. Biotech uses biological processes such as fermentation and harnesses biocatalysts such as enzymes, yeast, and other microbes to become microscopic manufacturing plants for a new type of agriculture. And as the days of the petrochemical companies wane, biofuels and biomass presage an new era of renewable energy. Biotech has advanced from being new and disruptive; to produce the bio-bricks new industries are built from.
Biotechnology Industry growth and trends
The global economy presents its own set of opportunities and threats for businesses in a range of industries.
New trends in biotechnology :Big data, Biosimilars, Clinical Omics,Ebola , Epigenetics, Immuno-Oncology, Nanomedicine, personalized medicines,synthetic biology.
In the stock market, biotech companies are now clearly in favor and the share prices of biotech companies have benefited. Investors are excited about the new products and technologies and are strong believers that the biotech business model is working.
This report on the biotechnology market analyses and estimates the global revenue generated by the biotechnology industry over the forecast period i.e. 2012 to 2017. The scope of the report considers biotechnology to be divided into four primary segments namely biopharmacy, bioservices, bioagriculture and bioindustrial. In terms of technology, the biotechnology market has been segmented into fermentation, tissue regeneration, PCR technology, nanobiotechnology, chromatography, DNA sequencing, cell based assay and others. The others segment comprises of genetic engineering, enzyme technology and fingerprinting among others.Industrial biotechnology conferences are to ameliorate the knowledge and to create awareness exclusively for Industries working on biotechnology
